

National Research Ethics Committee

NREC-CT Meeting

22nd October 2025

Attendance

| Name | Role |
|-------------------------------|---|
| Dr John Hayden (acting Chair) | Deputy Chairperson, NREC CT-B |
| Ms Serena Bennett | Committee Member, NREC-CT B |
| Dr Áine de Róiste | Committee Member, NREC-CT B |
| Dr Karina Halley | Committee Member, NREC-CT B |
| Prof. Michaela Higgins | Committee Member, NREC-CT B |
| Dr Ciaran Lee | Committee Member, NREC-CT B |
| Dr Andrew Lindsay | Committee Member, NREC-CT B |
| Dr Niall McGuinness | Committee Member, NREC-CT B |
| Prof. Seamus O'Reilly | Committee Member, NREC-CT B |
| Ms Evelyn O'Shea | Committee Member, NREC-CT B |
| Mr Ed McDonald | Committee Member, NREC-CT B |
| Dr Jane Bryant | Project Officer, National Office for RECs |
| Dr Laura Mackey | Programme Officer, National Office for RECs |
| Dr Susan Quinn | Programme Manager, National Office for RECs |
| Dr Peadar Rooney | Project Officer, National Office for RECs |
| Ms Chita Murray | Programme Manager, National Office for RECs |
| Ms Deirdre Ní Fhloinn* | Project Officer, National Office for RECs |

*Drafted minutes

Apologies: Ms Jasmine Joseph, Prof. Colm O'Donnell, Mrs Ann Twomey, Prof. John Wells

Quorum for decisions: Yes

Agenda

- Welcome & Apologies
- 2025-522731-34-00
- 2025-522632-14-00
- 2022-501352-28-00 SM-17
- 2022-502629-16-00 SM-6
- 2024-510800-35-00 SM-4
- 2023-505617-24-00 SM-6
- 2022-501007-28-00 SM-12
- 2023-510289-28-00 SM-2
- AOB

-
- The Chair welcomed the NREC-CT B.
 - The minutes from the previous NREC-CT B meeting on 24th September 2025 were approved.
 - The NREC Business Report was discussed and noted.
-

Applications

2025-522731-34-00

Institutions: Mater Misericordiae University Hospital

Study title: An open-label, fixed sequence Phase I study to evaluate the effect of Itraconazole (a strong CYP3A inhibitor) on the pharmacokinetics of AZ14170132, the TOP1 inhibitor payload of the antibody drug conjugate AZD5335, in participants with ovarian, primary peritoneal, or fallopian tube cancer

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**
- Request for Further Information

- **Additional Information Required RFI**

Part II Considerations

1. Financial arrangements

- The NREC-CT noted that carers of participants have not been included for travel and meal expense reimbursement in the Compensation Form (p1). The Committee

requested that reimbursement of travel and meal expenses are considered for carers of participants and, if included, that it is elucidated in the Compensation Form and PISCF's.

- The NREC-CT noted that neither participants nor carers will be reimbursed for accommodation in the Compensation Form (p1). The Committee requested that reimbursement of overnight accommodation expenses is considered for participants (and carers) if required and if included, that it is elucidated in the Compensation Form and PISCF's.

2. Subject information and informed consent form

- Standard Consideration:
 1. If applicable, the Sponsor is requested to submit any Part 2 documentation that require updates as a result of the Part 1 Assessment. Please include detail of the Part 1 consideration that triggered the update to the Part 2 documentation.
 2. All documentation provided in response to RFI should be presented in an accessible and searchable format (Word or original PDF). We are unable to accept scanned documents (including documents modified using Optical Character Recognition) as these documents cannot be optimised for use with assistive software.
- The NREC-CT noted a separate PISCF for Part B of the study. The Committee requested clarification on the merit of having two separate PISCF's when one consent form may suffice, with an optional consent section for Part B of the study included within it.

3. Suitability of the clinical trial sites facilities

- The NREC-CT noted that this is a new site in Ireland with multiple Phase 1 clinical trials. The Committee request clarification that capacity planning and adequate resourcing (including support for the Principal Investigator) at the site have been addressed, to ensure the dignity, safety and wellbeing of participants.

2025-522632-14-00

Institutions: Galway University Hospital, Beaumont Hospital, St James's Hospital, Mater Misericordiae University Hospital

Study title: A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects with Front-line Advanced NSCLC and Other Selected Indications

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Request for Further Information

- **Additional Information Required RFI**

Part II Considerations

1. Financial arrangements

- The NREC- CT noted that carers of participants have not been included for travel, accommodation and meal expense reimbursement in the Compensation Form (p1). The Committee requested that reimbursement of travel, accommodation and meal expenses are considered for carers of participants and, if included, that it is elucidated in the Compensation Form and PISCF's.
- The NREC-CT noted that participant reimbursement for travel and meals has been capped at 65euro maximum per study visit (Main PISCF pg 34). The Committee requested that this limit is reconsidered and that participants are reimbursed for all reasonable out of pocket expenses, to ensure equity in access to clinical trials across all socioeconomic groups.

2. Subject information and informed consent form

- Standard Consideration:
 1. If applicable, the Sponsor is requested to submit any Part 2 documentation that require updates as a result of the Part 1 Assessment. Please include detail of the Part 1 consideration that triggered the update to the Part 2 documentation.
 2. All documentation provided in response to RFI should be presented in an accessible and searchable format (Word or original PDF). We are unable to accept scanned documents (including documents modified using Optical Character Recognition) as these documents cannot be optimised for use with assistive software.
- The NREC-CT noted that despite the extensive list of (serious) side effects pertaining to the study medications in the Main PISCF (pg 14-29), there is minimal information given on the management of same. Furthermore, while the possibility of dose reductions of the IMP are outlined in the Protocol (pg 81), this information is absent from the PISCF. The Committee requested that further information on the management of side effects is elucidated in the PISCF and consideration is given to the inclusion of a statement confirming that side effects of the study medications will be addressed appropriately and participants supported accordingly by the study doctor.
- The NREC-CT noted the sentence “Your study doctor will be required to collect information about the outcome of your partner’s pregnancy and provide this information to the sponsor” in the Main PISCF (p32), however collection of pregnant partner data is described as optional in the Pregnancy PISCF (pg 3). The NREC-CT requested clarification on whether the collection of data from pregnant partners is optional and that that this is explained in both PISCF's such that the participant/pregnant partner is informed. If collection of this data is considered to be mandatory, please provide a justification.
- The NREC-CT noted that a GP letter has not been provided. The Committee requested that a GP letter is submitted for review if applicable.
- The NREC-CT noted the sentence “This authorization does not have an expiration date. If you do not withdraw authorization in writing, it will remain in effect indefinitely” (Main PISCF pg 37). The Committee requested that an option to verbally withdraw from study participation be included in the PISCF. In addition, the Committee requested that that the minimum duration of 25 years for data retention (as per article 58 of the EU Clinical Trial Regulation 536/2014) is clearly outlined in the PISCF.

- The NREC-CT noted bundled consent in the Pregnancy PISCF (pg 7). The Committee requested that the consent section be unbundled in all PISCF's, with a 'Yes/No' tick box available for each consent statement.
- The NREC-CT noted two consent statements below the signature section for the pregnant participant/partner in the Pregnancy PISCF (pg 6/ 7) and requested that these two consent statements are relocated above the signature section to ensure explicit informed consent.
- The NREC-CT noted the sentence "ask your doctor or nurse...if you are unsure which costs will be billed to you or your insurance provider" in the Main PISCF (pg 35). The Committee requested that this sentence is removed, and clarification is provided that no costs to the participant will be incurred.
- Please submit a CV for [REDACTED] using either the NREC or EMA template (available at <https://www.nrecoffice.ie/part-ii-national-requirements>) with all sections, including previous clinical trial experience, completed. This document does not require a signature. Please submit an accessible and searchable version (Word document or original PDF) of the CV. We are unable to accept scanned documents (including documents modified using Optical Character Recognition) as these documents cannot be optimised for use with assistive software.
- The NREC-CT cannot accept Site Suitability Assessments (SSA's) signed by the Principal Investigator (PI). The SSA for University Hospital Galway must be signed by the CEO, Head of Clinic / Institution, Director of Research, Clinical Director, or delegate at each site. As a result of a Union Controls exercise led by the European Commission, it was highlighted that the PI as a site delegate signing the SSA is a potential conflict of interest.
- The NREC-CT noted that the future use of data / samples (including genetic research) is not described in line with regulations / best practice on pg. 38/42 of the Main PISCF. The NREC-CT requested that future use of samples / personal data is sufficiently explained to participants in the PISCF documents so as to constitute broad informed consent, as required under the Health Research Regulations (Data Protection Act 2018 (Section 36(2) (Health Research) Regulations 2018). Furthermore,
 - it should be confined to a specified disease, related diseases or drug under study in this trial. Consent can only be obtained where future use of samples and data is defined such that participants are fully informed. Please define 'the scope of the study' in the Main PISCF (pg. 38) and align with the Compliance of Biological Samples Form. In addition, please amend the consent statement 'I agree to have my biological specimens used for future research' in the Main PISCF (pg 42).
 - and/or that an option is provided to enable participants to consent to be contacted in the future about other research studies,
 - The PISCF should also make it clear to participants that subsequent research ethics review will be sought for specific research once clearly defined. For further guidance, please see: NREC guidance on use of biological samples and associated data - <https://www.nrecoffice.ie/guidance-on-use-of-biological-samples-and-associated-data/>

2022-501352-28-00 SM-17

Institutions: Beaumont Hospital, University Hospital Galway, St Vincent's University Hospital, St James's Hospital

Study title: A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with severe community-acquired pneumonia (sCAP)

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Request for Further Information

- **Additional Information Required RFI**

Part II Considerations raised

1. Subject information and informed consent form

- Standard Consideration:
 1. If applicable, the Sponsor is requested to submit any Part 2 documentation that require updates as a result of the Part 1 Assessment. Please include detail of the Part 1 consideration that triggered the update to the Part 2 documentation.
 2. All documentation provided in response to RFI should be presented in an accessible and searchable format (Word or original PDF). We are unable to accept scanned documents (including documents modified using Optical Character Recognition) as these documents cannot be optimised for use with assistive software
- The NREC-CT requested that all PISCF's be updated to include the EU clinical trial number for participants
- The NREC-CT noted that risks related to the study are clearly outlined In the 'Onepager SIS' but that potential benefits are not, despite being provided in the 'Summary SIS' (pg 3) and in the 'Consent to Continue Summary' (pg 10). The Committee requested that potential benefits be appropriately outlined in the Onepager SIS to balance the risk-benefit statement and to aid participant decision-making.

2022-502629-16-00 SM-6

Institutions: Rotunda Hospital

Study title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Request for Further Information

- **Additional Information Required RFI**

Part II Considerations raised

1. Subject information and informed consent form

Standard Consideration:

1. Where applicable, the Sponsor is requested to submit any Part 2 documentation requiring revision following the outcome of the Part 1 Assessment. Should an additional Request for Information (RFI) be required, please contact the National Office at clinicaltrials@nrec.ie. The request should include a concise summary of the Part 1 consideration(s) that necessitated the update to the Part 2 documentation.

2. All documentation submitted in response to a Request for Information (RFI) must be provided in a format that is both accessible and searchable, such as Microsoft Word or original (non-scanned) PDF files. Please note that scanned documents, including those processed using Optical Character Recognition (OCR), are not acceptable, as they cannot be optimised for compatibility with assistive technologies.

- The NREC-CT noted that the Investigator Brochure (IB) has been updated with the Serious Adverse Events (SAE's) of colitis and sepsis now listed as Treatment Emergent Adverse Events (TEAE's) of special interest, and that these were considered related to nipocalimab by the Investigator of Study 80202135ED11006 (IB, pg 123). While the incidence of both sepsis and colitis in related studies of nipocalimab appears to be low, the Committee seek justification for the exclusion of these SAEs from the Maternal PISCF.
- The NREC-CT noted the title for 'NREC' is incorrectly listed as 'the National Office for Research Ethics Committees' (Pg 2 'Maternal PISCF and Parent PISCF). The Committee requested that the title for NREC is corrected to 'National Research Ethics Committee' in both PISCF's.
- The NREC-CT noted updates in the Maternal PISCF to the section entitled 'Optional Collection of Additional cffDNA Samples' (pg. 24) and requests that if these updates impact the ongoing performance study '24-NREC-MD-025', that a separate submission to the NREC-MD is submitted.

2024-510800-35-00 SM-4

Institutions: Cork University Hospital, University Hospital Galway, Beaumont Hospital

Study title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Request for Further Information

- **Additional Information Required RFI**

Part II Considerations raised

1. Subject information and informed consent form

Standard Consideration:

1. Where applicable, the Sponsor is requested to submit any Part 2 documentation requiring revision following the outcome of the Part 1 Assessment. Should an additional Request for Information (RFI) be required, please contact the National Office at clinicaltrials@nrec.ie. The request should include a concise summary of the Part 1 consideration(s) that necessitated the update to the Part 2 documentation.

2. All documentation submitted in response to a Request for Information (RFI) must be provided in a format that is both accessible and searchable, such as Microsoft Word or original (non-scanned) PDF files. Please note that scanned documents, including those processed using Optical Character Recognition (OCR), are not acceptable, as they cannot be optimised for compatibility with assistive technologies.

- The NREC-CT requested that Main and Optional Future Research PIS/ICF be updated to include the EU clinical trial number for participants
- The NREC-CT noted that page 3 of the Main ICF includes a witness signature line. The Committee requests that information be added to the ICF explaining the context when a witness signature would be needed (as per CTR: Annex I, L 62(b)).
- The NREC-CT noted the use of the words “additional mandatory research” in the Main ICF (pg 2) which could potentially cause confusion by appearing to contradict the future research referred to in the Optional Future Research ICF, which is clearly outlined as optional. The Committee requested that all additional research is further clarified in the Main PISCF and that a distinction is made between optional future research and additional mandatory research if applicable.
- The NREC-CT noted that the future use of data / samples (including genetic research) is not described in line with regulations / best practice on pg. 1/2 of the Optional Future Research PISCF’s. The NREC-CT requested that future use of samples / personal data is sufficiently explained to participants in the PISCF documents so as to constitute broad informed consent, as required under the Health Research Regulations (Data Protection Act 2018 (Section 36(2) (Health Research) Regulations 2018).
- Furthermore,
 1. it should be confined to a specified disease, related diseases or drug under study in this trial. Consent can only be obtained where future use of samples and data is defined such that participants are fully informed
The Committee requested updates to applicable sections of the document, including but not limited to the following: Optional Future Research ICF (pg. 2) and Optional Future Research PIS the sentence

- 'This research may involve looking at biomarkers not related to the study drug or your disease' and Optional Future Research ICF (pg. 2) the sentence 'I have read this informed consent and allow the performance of further research not related to this current study'
2. and/or that an option is provided to enable participants to consent to be contacted in the future about other research studies,
 3. for further guidance, please see: NREC guidance on use of biological samples and associated data - <https://www.nrecoffice.ie/guidance-on-use-of-biological-samples-and-associated-data/>

2023-505617-24-00 SM-6

Institutions: St James's Hospital, Beaumont Hospital, Bon Secours Hospital Cork, Marer Misericordiae University Hospital

Study title: A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Favourable

2022-501007-28-00 SM-12

Institutions: University Hospital Galway, Beacon Hospital, Cork University Hospital, St James's Hospital, Beaumont Hospital, Bon Secours Hospital Cork, University Hospital Waterford, St Vincent's University Hospital, Sligo University Hospital

Study title: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH EMBER-4)

Dossiers Submitted: Part II

- **NREC-CT Decision:**

- Favourable

2023-510289-28-00 SM-2

Institutions: St James's Hospital

Study title: A Phase 2, Open-label, Multicenter Study of Mitapivat in Subjects With Sickle Cell Disease and Nephropathy

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Favourable
-

- AOB:

- N/A